Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

AMY KATHRYN KRIE

Allopathic & Osteopathic Physicians Internal Medicine Medical Oncology

NPI
1083648075
CMS profile
507995
Location
MINNEAPOLIS, MN

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$230,927.60

216 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2025 · entire year · sorted by reported total

By paying entity

PY2025 · entire year · sorted by reported total

Paying entityAmountRecords
AstraZeneca Pharmaceuticals LP $102,050.17 90
Daiichi Sankyo Inc. $60,921.63 54
Gilead Sciences, Inc. $38,752.17 41
Stemline Therapeutics Inc. $29,203.63 31

Page 5 of 5; records 201–216 of 216 matching records. This page contains 16 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

AMY KATHRYN KRIE

NPI 1083648075 · CMS profile ID 507995

Allopathic & Osteopathic Physicians / Internal Medicine / Medical Oncology

MINNEAPOLIS, MN

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 5 of 5; records 201–216 of 216 matching records. This page contains 16 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1083648075?year=2025&recipient=provider&page=5#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
AMY KATHRYN KRIE, NPI 1083648075, CMS profile ID 507995. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 5 of 5; records 201–216 of 216 matching records. This page contains 16 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1083648075?year=2025&recipient=provider&page=5#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). AMY KATHRYN KRIE, NPI 1083648075, CMS profile ID 507995. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 5 of 5; records 201–216 of 216 matching records. This page contains 16 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1083648075?year=2025&recipient=provider&page=5#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
AMY KATHRYN KRIE, NPI 1083648075, CMS profile ID 507995, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 5 of 5; records 201–216 of 216 matching records. This page contains 16 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1083648075?year=2025&recipient=provider&page=5#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

216 matching records · $230,927.60 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 216 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 201–216 of 216.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Gilead Sciences, Inc. $40.0901/29/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1234372981 CMS
Gilead Sciences, Inc. $27.9201/29/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1234452056 CMS
Gilead Sciences, Inc. $8.7801/29/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1234589704 CMS
Gilead Sciences, Inc. $5.4501/29/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1234601200 CMS
AstraZeneca Pharmaceuticals LP $5,360.0001/28/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1207200780 CMS
Gilead Sciences, Inc. $199.0001/28/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1234369898 CMS
Gilead Sciences, Inc. $20.7501/28/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1234520661 CMS
Gilead Sciences, Inc. $17.2901/28/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1234555333 CMS
Gilead Sciences, Inc. $15.1201/28/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1234571356 CMS
Gilead Sciences, Inc. $13.1001/28/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1234581060 CMS
Gilead Sciences, Inc. $5.4501/28/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1234601198 CMS
AstraZeneca Pharmaceuticals LP $406.9401/22/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1206826355 CMS
AstraZeneca Pharmaceuticals LP $123.6301/22/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1206864778 CMS
AstraZeneca Pharmaceuticals LP $209.8101/22/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1207279903 CMS
AstraZeneca Pharmaceuticals LP $670.0001/21/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1206680670 CMS
Daiichi Sankyo Inc. $416.2501/08/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1197097217 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $44,630.33 48
PY2020 $76,089.25 89
PY2021 $45,304.99 48
PY2022 $103,303.53 109
PY2023 $182,004.99 141
PY2024 $224,990.63 190
PY2025 $230,927.60 216

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $670,613.85 30
PY2024 Recipient $2,310.00 1
PY2024 Principal investigator $208,067.30 10
PY2023 Recipient $1,989.22 1
PY2023 Principal investigator $72,192.18 21
PY2022 Principal investigator $70,957.45 17
PY2021 Principal investigator $366,141.35 25
PY2020 Principal investigator $54,009.11 22
PY2019 Principal investigator $116,865.82 27

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

30 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Merck Sharp & Dohme LLC $175.09 12/31/2025 Covered Recipient Teaching Hospital
Abbott Northwestern Hospital
A Randomized, Double-Blind, Phase III Study of Pembrolizumab MK-3475 plus Chemotherapy vs Placebo plus Chemotherapy for Previously Untreated Locally Recurrent Inoperable or Metastatic Triple Negative Breast Cancer - KEYNOTE-355 No dispute reported 06/30/2026 1232926021
Principal investigator 1 PFIZER INC. $8,916.87 12/27/2025 Covered Recipient Teaching Hospital
Mercy Hospital
AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 No dispute reported 06/30/2026 1228749157
Principal investigator 1 PFIZER INC. $5,657.31 12/13/2025 Covered Recipient Teaching Hospital
Mercy Hospital
AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 No dispute reported 06/30/2026 1228743757
Principal investigator 1 PFIZER INC. $30.00 12/08/2025 Covered Recipient Teaching Hospital
Mercy Hospital
AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 No dispute reported 06/30/2026 1228712410
Principal investigator 1 PFIZER INC. $21,256.38 11/26/2025 Covered Recipient Teaching Hospital
Mercy Hospital
AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 No dispute reported 06/30/2026 1228728201
Principal investigator 1 PFIZER INC. $13,348.53 11/05/2025 Covered Recipient Teaching Hospital
Mercy Hospital
AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 No dispute reported 06/30/2026 1228729426
Principal investigator 1 PFIZER INC. $6,960.44 10/31/2025 Covered Recipient Teaching Hospital
Mercy Hospital
AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 No dispute reported 06/30/2026 1228729933
Principal investigator 1 PFIZER INC. $30.00 10/27/2025 Covered Recipient Teaching Hospital
Mercy Hospital
AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 No dispute reported 06/30/2026 1228712272
Principal investigator 1 PFIZER INC. $173.75 10/09/2025 Covered Recipient Teaching Hospital
Mercy Hospital
AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 No dispute reported 06/30/2026 1228741844
Principal investigator 1 PFIZER INC. $57,300.60 09/24/2025 Covered Recipient Teaching Hospital
Mercy Hospital
AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 No dispute reported 06/30/2026 1228712214
Principal investigator 1 PFIZER INC. $30.00 09/24/2025 Covered Recipient Teaching Hospital
Mercy Hospital
AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 No dispute reported 06/30/2026 1228712274
Principal investigator 1 PFIZER INC. $8,902.97 09/24/2025 Covered Recipient Teaching Hospital
Mercy Hospital
AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 No dispute reported 06/30/2026 1228770934
Principal investigator 1 PFIZER INC. $3,544.85 09/09/2025 Covered Recipient Teaching Hospital
Mercy Hospital
AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 No dispute reported 06/30/2026 1228771244
Principal investigator 1 Merck Sharp & Dohme LLC $34,811.71 08/31/2025 Covered Recipient Teaching Hospital
Abbott Northwestern Hospital
A Phase 3, Randomized, Open-label Study Comparing Efficacy and Safety of Sacituzumab Tirumotecan sac-TMT, MK-2870 as a Monotherapy and in Combination with PembrolizumabMK-3475 Versus Treatment of Physician's Choice in Participants With Previously Untr No dispute reported 06/30/2026 1232922980
Principal investigator 1 PFIZER INC. $5,004.01 08/29/2025 Covered Recipient Teaching Hospital
Mercy Hospital
AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 No dispute reported 06/30/2026 1228766718
Principal investigator 1 PFIZER INC. $22.50 08/15/2025 Covered Recipient Teaching Hospital
Mercy Hospital
AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 No dispute reported 06/30/2026 1228712348
Principal investigator 1 PFIZER INC. $6,258.83 07/31/2025 Covered Recipient Teaching Hospital
Mercy Hospital
AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 No dispute reported 06/30/2026 1228763225
Principal investigator 1 PFIZER INC. $15.00 07/25/2025 Covered Recipient Teaching Hospital
Mercy Hospital
AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 No dispute reported 06/30/2026 1228712212
Principal investigator 1 PFIZER INC. $28,830.00 07/16/2025 Covered Recipient Teaching Hospital
Mercy Hospital
AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 No dispute reported 06/30/2026 1228781630
Principal investigator 1 PFIZER INC. $16,330.08 07/01/2025 Covered Recipient Teaching Hospital
Mercy Hospital
AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 No dispute reported 06/30/2026 1228712412
Principal investigator 1 PFIZER INC. $57,300.60 06/23/2025 Non-covered Recipient Entity
Allina Health Cancer Institute
AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 No dispute reported 06/30/2026 1228768550
Principal investigator 1 PFIZER INC. $15.00 06/23/2025 Non-covered Recipient Entity
Allina Health Cancer Institute
AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 No dispute reported 06/30/2026 1228771472
Principal investigator 1 PFIZER INC. $17,200.00 03/07/2025 Covered Recipient Teaching Hospital
Mercy Hospital
A PHASE 1 STUDY OF SGNB6A IN ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228790008
Principal investigator 1 PFIZER INC. $5,500.00 02/18/2025 Covered Recipient Teaching Hospital
Mercy Hospital
A SINGLE ARM OPEN LABEL PHASE 2 STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB DERUXTECAN IN SUBJECTS WITH PREVIOUSLY TREATED UNRESECTABLE LOCALLYADVANCED OR METASTATIC HER2 BREAST CANCER No dispute reported 06/30/2026 1228787702
Principal investigator 1 PFIZER INC. $5,500.00 02/18/2025 Covered Recipient Teaching Hospital
Mercy Hospital
A SINGLE ARM OPEN LABEL PHASE 2 STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB DERUXTECAN IN SUBJECTS WITH PREVIOUSLY TREATED UNRESECTABLE LOCALLYADVANCED OR METASTATIC HER2 BREAST CANCER No dispute reported 06/30/2026 1228789187
Principal investigator 1 PFIZER INC. $10,000.00 02/03/2025 Covered Recipient Teaching Hospital
Mercy Hospital
THE COMPASSHER2 TRIALS COMPREHENSIVE USE OF PATHOLOGIC RESPONSE ASSESSMENT TO OPTIMIZE THERAPY IN HER2POSITIVE BREAST CANCER COMPASSHER2 RESIDUAL DISEASE RD A DOUBLEBLINDED PHASE III RANDOMIZED TRIAL OF TDM1 COMPARED WITH TDM1 AND TUCATINIB No dispute reported 06/30/2026 1228781527
Principal investigator 1 PFIZER INC. $10,000.00 02/03/2025 Covered Recipient Teaching Hospital
Mercy Hospital
THE COMPASSHER2 TRIALS COMPREHENSIVE USE OF PATHOLOGIC RESPONSE ASSESSMENT TO OPTIMIZE THERAPY IN HER2POSITIVE BREAST CANCER COMPASSHER2 RESIDUAL DISEASE RD A DOUBLEBLINDED PHASE III RANDOMIZED TRIAL OF TDM1 COMPARED WITH TDM1 AND TUCATINIB No dispute reported 06/30/2026 1228784133
Principal investigator 1 PFIZER INC. $3,500.00 02/03/2025 Covered Recipient Teaching Hospital
Mercy Hospital
SINGLE ARM OPEN LABEL PHASE 1B2 STUDY OF SGNLIV1A IN COMBINATION WITH PEMBROLIZUMAB FOR FIRSTLINE TREATMENT OF PATIENTS WITH UNRESECTABLE LOCALLYADVANCED OR METASTATIC TRIPLENEGATIVE BREAST CANCER No dispute reported 06/30/2026 1228792644
Principal investigator 1 Eli Lilly and Company $5,387.33 01/09/2025 Covered Recipient Teaching Hospital
UNITED HOSPITAL
EMBER-4: A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF ADJUVANT IMLUNESTRANT VS STANDARD ADJUVANT ENDOCRINE THERAPY IN PATIENTS WHO HAVE PREVIOUSLY RECEIVED 2 TO 5 YEARS OF ADJUVANT ENDOCRINE THERAPY FOR ER+, HER2- EARLY BREAST CANCER WITH AN INCREASED RISK OF RECURRENCE No dispute reported 06/30/2026 1187873563
Principal investigator 1 Eli Lilly and Company $338,612.00 01/07/2025 Covered Recipient Teaching Hospital
UNITED HOSPITAL
EMBER-4: A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF ADJUVANT IMLUNESTRANT VS STANDARD ADJUVANT ENDOCRINE THERAPY IN PATIENTS WHO HAVE PREVIOUSLY RECEIVED 2 TO 5 YEARS OF ADJUVANT ENDOCRINE THERAPY FOR ER+, HER2- EARLY BREAST CANCER WITH AN INCREASED RISK OF RECURRENCE No dispute reported 06/30/2026 1187873561